Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 5, 2009

Sigma-Aldrich and Sangamo Biosciences Broaden Agreement Related to Zinc-Finger Technology

  • Sigma-Aldrich and Sangamo BioSciences enacted an expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications.

    The companies first formed an alliance in 2007 focused on the development of laboratory research reagents based upon Sangamo’s ZFP technology. In July they reported development of the first genetically modified rats using zinc finger nuclease (ZFN) technology. Sigma-Aldrich markets Sangamo’s ZFN technology through its CompoZr™ line of products and services.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »